Literature DB >> 2184934

Cancer in ataxia-telangiectasia patients.

F Hecht1, B K Hecht.   

Abstract

A gene locus for ataxia-telangiectasia (A-T) is in chromosome region 11q22 to 11q23 and predisposes to cancer. Ataxia-telangiectasia patients appear to have two separate clinical patterns of malignancy. One pattern involves solid tumors, which have not been stressed and which include malignancies in the oral cavity, breast, stomach, pancreas, ovary, and bladder. Detection of a solid tumor in an A-T patient should serve as a warning. It heralds a markedly elevated risk of another malignancy in that patient. The second pattern of neoplasia in A-T is well recognized and consists of lymphocytic leukemia and non-Hodgkin's lymphoma. These malignancies may relate to immunodeficiency in A-T and to chromosome breakage and rearrangement, which are a feature of A-T. These two patterns of malignancy may be truly separate and reflect different mechanisms of malignancy in A-T, or they may not really be separate but instead reflect a single mechanism of malignancy. The situation in A-T is reminiscent of that in the acquired immunodeficiency syndrome (AIDS), in which Kaposi's sarcoma occurs with mild immunodeficiency and pneumocystis carinii pneumonia occurs with more profound immunodeficiency owing to the human immunodeficiency virus. Next to pulmonary disease, cancer is the leading cause of death in A-T.

Entities:  

Mesh:

Year:  1990        PMID: 2184934     DOI: 10.1016/0165-4608(90)90003-s

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  17 in total

1.  A novel mouse model for ataxia-telangiectasia with a N-terminal mutation displays a behavioral defect and a low incidence of lymphoma but no increased oxidative burden.

Authors:  Andrew Campbell; Brittany Krupp; Jared Bushman; Mark Noble; Christoph Pröschel; Margot Mayer-Pröschel
Journal:  Hum Mol Genet       Date:  2015-08-26       Impact factor: 6.150

Review 2.  Genetic and epigenetic features in radiation sensitivity. Part II: implications for clinical practice and radiation protection.

Authors:  Michel H Bourguignon; Pablo A Gisone; Maria R Perez; Severino Michelin; Diana Dubner; Marina Di Giorgio; Edgardo D Carosella
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03       Impact factor: 9.236

3.  Fragments of ATM which have dominant-negative or complementing activity.

Authors:  S E Morgan; C Lovly; T K Pandita; Y Shiloh; M B Kastan
Journal:  Mol Cell Biol       Date:  1997-04       Impact factor: 4.272

Review 4.  Cancer of the oral cavity.

Authors:  Pablo H Montero; Snehal G Patel
Journal:  Surg Oncol Clin N Am       Date:  2015-04-15       Impact factor: 3.495

5.  Maternal and perinatal risk factors for childhood brain tumors (Sweden).

Authors:  M S Linet; G Gridley; S Cnattingius; H S Nicholson; U Martinsson; B Glimelius; H O Adami; M Zack
Journal:  Cancer Causes Control       Date:  1996-07       Impact factor: 2.506

6.  Expression cloning of multiple human cDNAs that complement the phenotypic defects of ataxia-telangiectasia group D fibroblasts.

Authors:  M S Meyn; J M Lu-Kuo; L B Herzing
Journal:  Am J Hum Genet       Date:  1993-12       Impact factor: 11.025

7.  Deficiencies in CD4+ and CD8+ T cell subsets in ataxia telangiectasia.

Authors:  R Schubert; J Reichenbach; S Zielen
Journal:  Clin Exp Immunol       Date:  2002-07       Impact factor: 4.330

Review 8.  ATM-NF-kappaB connection as a target for tumor radiosensitization.

Authors:  Kazi Mokim Ahmed; Jian Jian Li
Journal:  Curr Cancer Drug Targets       Date:  2007-06       Impact factor: 3.428

9.  Illegitimate recombination between T cell receptor genes in humans and pigs (Sus scrofa domestica).

Authors:  Petra Musilova; Jitka Drbalova; Svatava Kubickova; Halina Cernohorska; Hana Stepanova; Jiri Rubes
Journal:  Chromosome Res       Date:  2014-07-20       Impact factor: 5.239

10.  CT and MR imaging of splenic leiomyoma in a child with ataxia telangiectasia.

Authors:  M Coşkun; U Aydingöz; T Tacal; M Ariyürek; F Demirkazik; L Oğuzkurt
Journal:  Pediatr Radiol       Date:  1995
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.